Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Akalin, Altuna Dr. (1) Berruezo Llacuna, Maria (1) Blankenstein, Thomas Prof. Dr. (9) Daniel, Peter Prof. Dr. (1) Di Virgilio, Michela Prof. Dr. (1) Driesner, Madlen (1) Filosa, Alessandro Dr. (1) Graf, Robin Dr. (2) Höpken, Uta Elisabeth PD Dr. (1) Janz, Martin Dr. (10) Jeuthe, Sarah Dr. (1) Kammertöns, Thomas Dr. (6) Keller, Lisa (1) Keller, Ulrich Dr. med. (2) Kocks, Christine Dr. (1) Landthaler, Markus Prof. Dr. (1) Leutz, Achim Prof. Dr. (1) Mertins, Philipp Dr. (1) Nguyen, Tam Hoai Dr. (1) Pezzutto, Antonio Prof. Dr. (1) Popp, Oliver Dr. (1) Prigione, Alessandro Prof. Dr. (1) Rajewsky, Klaus Prof. Dr. (1) Rathjen, Fritz Prof. Dr. (1) Rehm, Armin Dr. (1) Sawamiphak, Suphansa Dr. (1) Selbach, Matthias Prof. Dr. (10) Uckert, Wolfgang Prof. Dr. (2) Zauber, Henrik Dr. (1) (-) Leisegang, Matthias Prof. Dr. rer. nat. (2) (-) Lusatis, Simone (1) (-) Mathas, Stephan Dr. (8) (-) Wollert-Wulf, Brigitte (2) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (1) (-) 2004 (2) 2005 (2) (-) 2006 (5) 2007 (3) 2008 (4) 2009 (3) 2010 (4) 2011 (5) 2012 (1) 2013 (3) 2014 (3) 2015 (7) 2016 (3) 2017 (4) 2018 (3) 2019 (2) (-) 2020 (4) 2021 (3) 2022 (5) 2023 (9) 2024 (1) Bioinformatics and Omics Data Science (1) (-) Biology of Malignant Lymphomas (9) Genetics and Genomics of Cardiovascular Diseases (1) Genome Engineering & Disease Models (1) Immune Regulation and Cancer (2) Mechanism-based Cancer Therapies (2) (-) Molecular Immunology and Gene Therapy (2) Proteomics (1) Transgenics (1) 11 Results: Active Filter: Leisegang, Matthias Prof. Dr. rer. nat.Lusatis, SimoneMathas, Stephan Dr.Wollert-Wulf, BrigitteBiology of Malignant LymphomasMolecular Immunology and Gene Therapy200420062020 Sort: Result score Newest to oldest Oldest to newest December 01, 2020 / Front Immunol B-cell-specific Myd88 L252P expression causes a premalignant gammopathy resembling IgM MGUS K. Schmidt U. Sack R. Graf W. Winkler O. Popp P. Mertins T. Sommermann C. Kocks K. Rajewsky December 17, 2020 / Blood Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 S. Reinke P.J. Bröckelmann I. Iaccarino M. Garcia-Marquez S. Borchmann F. Jochims M. Kotrova K. Pal M. Brüggemann E. Hartmann S. Sasse C. Kobe S. Mathas M. Soekler U. Keller M. Bormann A. Zimmermann J. Richter M. Fuchs B. von Tresckow P. Borchmann H. Schlößer M. von Bergwelt-Baildon A. Rosenwald A. Engert W. Klapper February 07, 2020 / EMBO Mol Med "Designer cytokines" targeting the tumor vasculature - think global and act local T. Kammertoens J. Kemna M. Leisegang June 01, 2020 / JAMA Oncol Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial P.J. Bröckelmann H. Goergen U. Keller J. Meissner R. Ordemann T.V. Halbsguth S. Sasse M. Sökler A. Kerkhoff S. Mathas A. Hüttmann M. Bormann A. Zimmermann J. Mettler M. Fuchs B. von Tresckow C. Baues A. Rosenwald W. Klapper C. Kobe P. Borchmann A. Engert March 15, 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou February 01, 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken January 01, 2004 / Blood Jagged1-induced notch signaling drives proliferation of multiple myeloma cells F. Jundt K. Schulze-Proebsting I. Anagnostopoulos G. Muehlinghaus M. Chatterjee S. Mathas R.C. Bargou R. Manz H. Stein B. Doerken April 19, 2004 / J Exp Med c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis S. Mathas A. Lietz I. Anagnostopoulos F. Hummel B. Wiesner M. Janz F. Jundt B. Hirsch K. Joehrens-Leder H.P. Vornlocher K. Bommert H. Stein B. Doerken November 01, 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert May 15, 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas Pagination Current page 1 Page 2 Next page Next › Last page Last »
December 01, 2020 / Front Immunol B-cell-specific Myd88 L252P expression causes a premalignant gammopathy resembling IgM MGUS K. Schmidt U. Sack R. Graf W. Winkler O. Popp P. Mertins T. Sommermann C. Kocks K. Rajewsky
December 17, 2020 / Blood Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 S. Reinke P.J. Bröckelmann I. Iaccarino M. Garcia-Marquez S. Borchmann F. Jochims M. Kotrova K. Pal M. Brüggemann E. Hartmann S. Sasse C. Kobe S. Mathas M. Soekler U. Keller M. Bormann A. Zimmermann J. Richter M. Fuchs B. von Tresckow P. Borchmann H. Schlößer M. von Bergwelt-Baildon A. Rosenwald A. Engert W. Klapper
February 07, 2020 / EMBO Mol Med "Designer cytokines" targeting the tumor vasculature - think global and act local T. Kammertoens J. Kemna M. Leisegang
June 01, 2020 / JAMA Oncol Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial P.J. Bröckelmann H. Goergen U. Keller J. Meissner R. Ordemann T.V. Halbsguth S. Sasse M. Sökler A. Kerkhoff S. Mathas A. Hüttmann M. Bormann A. Zimmermann J. Mettler M. Fuchs B. von Tresckow C. Baues A. Rosenwald W. Klapper C. Kobe P. Borchmann A. Engert
March 15, 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
February 01, 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
January 01, 2004 / Blood Jagged1-induced notch signaling drives proliferation of multiple myeloma cells F. Jundt K. Schulze-Proebsting I. Anagnostopoulos G. Muehlinghaus M. Chatterjee S. Mathas R.C. Bargou R. Manz H. Stein B. Doerken
April 19, 2004 / J Exp Med c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis S. Mathas A. Lietz I. Anagnostopoulos F. Hummel B. Wiesner M. Janz F. Jundt B. Hirsch K. Joehrens-Leder H.P. Vornlocher K. Bommert H. Stein B. Doerken
November 01, 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
May 15, 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas